Maarten Albersen

Maarten Albersen


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
ATAnita Thomas
Anita Thomas
Andrea NecchiAndrea Necchi
Andrea Necchi
AMAsif Muneer
Asif Muneer
MTMarcos Tobias-Machado
Marcos Tobias-Machado
ATAnna Thi Huyen Tran
Anna Thi Huyen Tran
MAMaarten Albersen
Maarten Albersen

1 October 2010 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
MAMaarten Albersen
Maarten Albersen
TFThomas M. Fandel
Thomas M. Fandel
GLGuiting Lin
Guiting Lin
GWGuifang Wang
Guifang Wang
LBLia Banie
Lia Banie
TLTom F. Lue
Tom F. Lue

1 March 2013 in European Urology
Verified
Journal Article
Closed access
FCFabio Castiglione
Fabio Castiglione
PHPetter Hedlund
Petter Hedlund
FAFrank Van der Aa
Frank Van der Aa
TBTrinity J. Bivalacqua
Trinity J. Bivalacqua
PRPatrizio Rigatti
Patrizio Rigatti
MAMaarten Albersen
Maarten Albersen

1 January 2012 in European Urology
Verified
Journal Article
Closed access
TFThomas M. Fandel
Thomas M. Fandel
MAMaarten Albersen
Maarten Albersen
GLGuiting Lin
Guiting Lin
XQXuefeng Qiu
Xuefeng Qiu
HNHongxiu Ning
Hongxiu Ning
CLChing-Shwun Lin
Ching-Shwun Lin

1 October 2012 in European Urology
Verified
Journal Article
Closed access
XQXuefeng Qiu
Xuefeng Qiu
TFThomas M. Fandel
Thomas M. Fandel
LFLudovic Ferretti
Ludovic Ferretti
MAMaarten Albersen
Maarten Albersen
HZHaiyang Zhang
Haiyang Zhang
TLTom F. Lue
Tom F. Lue

23 April 2010 in Expert Opinion on Emerging Drugs
Verified
Journal Article
Closed access
MAMaarten Albersen
Maarten Albersen
ASAlan W Shindel
Alan W Shindel
KMKuwong B Mwamukonda
Kuwong B Mwamukonda
TLTom F Lue
Tom F Lue
Importance of the field: Erectile dysfunction (ED) is the most common male sexual dysfunction presented for treatment affecting between 10 and 20% of men. PDE type 5 inhibitors (PDE5I) now account ...